Funding for this research was provided by:
Received: 15 December 2020
Accepted: 11 January 2021
First Online: 1 March 2021
Ethics approval and consent to participate
: Independent review board approval was obtained prior to all study related activity from the ethical committee of the University of Tübingen (protocol no. 270/2015BO1). Written informed consent was obtained from all patients before enrollment.
: Not applicable.
: Florian Härtig received reimbursement for congress traveling and accommodation from Bayer and Daiichi Sankyo. Ingvild Birschmann received speaker’s honoraria from Bristol-Myers Squibb/Pfizer, Siemens Healthcare and CSL Behring and reimbursement for congress traveling and accommodation from Aspen and Bristol-Myers Squibb and performed contract research for Siemens Healthcare. She is a member of the advisory board of LFB biomedicaments. Ulf Ziemann received has received personal fees from Biogen Idec, Bayer Vital, Bristol-Myers Squibb/Pfizer, CorTec, and grants from Biogen Idec, Janssen Pharmaceutica NV, and Takeda. Sven Poli received speaker’s honoraria and consulting honoraria from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo and Werfen, reimbursement for congress traveling and accommodation from Bayer and Boehringer-Ingelheim, and research support from Bristol-Myers Squibb/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo. The remaining authors have declared that they do not have any conflicts of interest.